Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
The Journal of Practical Medicine ; (24): 2092-2096, 2017.
Artigo em Chinês | WPRIM | ID: wpr-617029

RESUMO

Objective To investigate the effect of salinomycin on cancer stem cell formation of prostate cancer cell line DU145 and its possible mechanisms,providing theoretical basis for the clinical application of salino-mycin. Methods (1)DU145 cells were treated with salinomycin. The percentage of ALDH+cells,which was used as the marker of cancer stem cells,was detected by flow cytometry.(2)After treated with salmonin,DU145 cells were subjected to Western-Blot analysis for the expression of mTORsignal pathway-related proteins such as p-70s6k, p-p70s6,p-s6 and so on. 3)DU145 cells were treated with salinomycin combined with mTOR signal pathway inhibi-tor rapamycin,and the ALDH+cancer stem cells were detected using flow cytometer. Results (1)Salmonomycin significantly inhibited ALDH-positive cancer stem cells in DU145cell line(inhibition rate in 77.8%),which was twice as high as that of traditional anticancer drug paclitaxel(which has a inhibition rate of 38.64%). This results suggesting that salinomycin would have the effect of inhibiting cancer stem cells. (2)The expression ofm-TOR p-70s6k,p-p70s6 and p-s6 in mTOR signaling pathway was inhibited by salinomycin in a time-dependent and dose-dependent manner,suggesting that salinomycin would inhibite mTOR signaling pathway.(3)Salinomycin combined with rapamycin can decrease the proportion of ALDH-positive DU145 cancer stem cells(inhibition rate in 77.95%), suggesting that salinomycin may inhibit ALDH-positive DU145 stem cells through the mTOR signaling pathway. Conclusion Salinomycin may play an important role in inhibiting cancer stem cells by inhibiting mTOR pathway signaling.

2.
Chinese Journal of Experimental and Clinical Virology ; (6): 401-404, 2017.
Artigo em Chinês | WPRIM | ID: wpr-808647

RESUMO

Objective@#To investigate the change of hepatitis B surface antibody (HBsAb) titer and its long-term protection and infection rates between 1 and 3-year-old children whose mothers were chronic hepatitis B pregnant woman with HBeAg positive and high viral load after successful blocking of mother-to-child transmission.@*Methods@#One-year-old children whose mothers were hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive, with HBV DNA≥106IU/ml were enrolled, then were followed up till 3 years old, and tested the five serological markers of hepatitis B and biochemical parameters at the age of one and three years respectively, and analyzed HBsAb titer, positive rate, negative rate and infection rate of 1 to 3-year-old children without enhanced vaccination; meanwhile, data of HBsAb titers at the age of 7 months were collected HBsAb titer, positive rate, and negative rate were analyzed.@*Results@#Totally 264 1-year-old children were enrolled into the study, including 178 children without enhanced vaccination between seven months and 1 year of age, and 114 children without enhanced vaccination between 1 year and 3 years of age. Our result showed that there were no infected children at the age between 1 and 3 years. HBsAb titer decreased from 7 months to 1 year old and dropped from 1 000 IU/L to 509.43 IU/L (P<0.05), and the antibody was still protective. From 1 year to 3 years old, HBsAb titer dropped from 466.72 IU/L to 67.3 IU/L (P< 0.05); at the age of 3 years, 60.52 % children were either weakly positive or negative, but still protective, but significantly less than those who had the reinforced vaccination. As a result , the children without the enhanced vaccination between 1 and 3 years of age were still at high risk.@*Conclusions@#If the antibody was protective at 7 months, children were not easily infected between 1 year and 3 years of age. At the age of 3, the antibody dropped to low or no responsive levels, and the children were still at high risk. It is necessary to take protective measures and supplement the vaccine.

3.
International Journal of Laboratory Medicine ; (12): 317-318,321, 2015.
Artigo em Chinês | WPRIM | ID: wpr-600672

RESUMO

Objective To investigate the value of G6PI in the diagnosis of rheumatoid arthritis(RA).Methods The clinical data of 130 cases of patients with RA treated in the hospital from August 2011 to August 2013 were statistically analyzed.In addition to that,85 non-RA patients with other rheumatic diseases were recruited as non-RA group and 60 healthy people were recruited as control group.Results Serum G6PI,anti-CCP antibodies and RF concentrations of RA group were significantly higher than those of non-RA group and control group(P <0.05),the RF concentrations of non-RA group was significantly higher than those of con-trol group(P <0.05).The positive rates of G6PI,anti-CCP antibodies and RF tests were 67.7%(88/130),52.3%(68/130)and 75.4% (98/130)respectively in RA group,which were significantly higher than those in non-RA and control group(P <0.05),the serum RF concentrations in non-RA group were significantly higher than control group(P <0.05).The sensitivity,negative predic-tive value and Youden index of G6PI were significantly higher than those of anti-CCP and RF(P <0.05).Serum G6PI concentra-tions of RA patients was positively correlated with those of RF(r=0.732,P <0.05).Conclusion G6PI detection can be used in the diagnosis of RA,and is of great value.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA